Dr. Jeffery Nielsen is Cheif Technology Officer at Eradivir, overseeing the early discovery and preclinical development efforts for the pipeline of Eradivir. Eradivir develops targeted small molecule drugs that recruit the immune system to clear diseased cells. He received his PhD in Medicinal Chemistry at Purdue University under legendary drug developer Phil Low. He has spent the last 13 years on early drug discovery and development. Overseeing research efforts at Biofire diagnostics, Novosteo, Cortexyme, Quince Therapeutics and Eradivir. Two products he was part of the discovery team for are now FDA approved and marketed. Dr Nielsen has founded or co-founded 4 successful companies in 2 different industries. He has published 27 peer reviewed journal articles and abstracts and is a primary inventor on 43 US and international patents/patents pending.